Takeda’s agreement with Innovent Biologics brings cancer drugs that could become contributors to a portfolio that’s facing the patent cliff. The pharmaceutical giant’s strategy for finding new blockbuster prospects spans internally discovered drugs and in-licensed assets.
The post Takeda Boosts Pipeline and Revenue Growth Prospects With $1.2B Deal for Innovent Cancer Drugs appeared first on MedCity News.
